Antisense oligonucleotides used to treat prion disease in animal models
Researchers have shown that using antisense oligonucleotides to reduce the levels of prion protein in lab animals with prion disease can extended their survival.
List view / Grid view
Researchers have shown that using antisense oligonucleotides to reduce the levels of prion protein in lab animals with prion disease can extended their survival.
The SARS-CoV-2 Spike protein from a COVID-19 vaccine candidate has been characterised by researchers, supporting the neutralising antibody response it elicits.
A study in older mice with type 2 diabetes revealed a tuberculosis vaccine elicited a strong immune response, making it a promising candidate for the condition.
A team has found that a mutation in the ATAXIN-1 gene causes spinocerebellar ataxia type 1 (SCA1), presenting a drug target for the condition.
Five immune response biomarkers have been identified by researchers who say they can be used to classify which COVID-19 patients will survive the disease.
A flow mode Raman-activated cell sorter called FlowRACS has been created by researchers for high-throughput discovery of enzymes and their cell factories.
A machine learning algorithm that predicts sites of DNA methylation could aid in the identification of disease-causing mechanisms, say researchers.
Researchers have found the small molecules Apilimod and Vacuolin-1 inhibited the PIKfyve kinase in cells, preventing infection from Zaire ebolavirus and SARS-CoV-2.
An α-radioimmunotherapy called 212Pb-anti-CD38 was effective at preventing tumour growth and increasing survival in multiple myeloma tumour-bearing mice, a study has shown.
Researchers have sequenced SARS-CoV-2, revealing at least six strains with little variability, useful information for vaccine developers.
Researchers have found the TBK1 enzyme regulates the degradation and clearance of the huntingtin protein, making it a drug target for Huntington's disease.
A drug called CMS121 given to mice with Alzheimer's-like disease treated their memory loss, allowing them to perform the same as healthy control mice in tests.
A new decoy receptor of ACE2 has been created which binds to and neutralises COVID-19 in live tissue cultures, preventing cells from becoming infected.
A new FXII inhibitor has been developed that efficiently blocked coagulation in a thrombosis model without increasing the risk of bleeding.
A phenotypic chemical screen has been developed that could be used to discover molecular glue degraders which induce the degradation of target proteins.